No-Cost, No-Obligation Zantac Cancer Attorney Case Review

Antacid Cancer Attorney
Zantac Lawsuit News

Popular Anti-acid Drugs May Contain a Compound That is Proven To Cause Cancer

Over 60 million Americans that take anti-acid reflux medications may be at risk of having developed stomach or bladder cancer

Monday, April 6, 2020 - It seems as if every day another drug whose safety we have taken for granted for years is suspected of causing a disease that is worse than the condition it was intended to treat. Television and print advertising designed to maximize sales highlight the benefits of the drugs making the public think it is safe while barely mentioning the drug's potential side effects. Even commercials that do mention a drug's side effects, usually do so at the very end and do not give them the weight they deserve. Take for example Zantac, an anti-heartburn drug taken by millions of individuals to treat periodic episodes of gastroesophageal reflux disease (GERD), better known as acid reflux. Zantac is the latest in a serious of presumably safe drugs that are now suspected of containing a carcinogen that is known to cause stomach and bladder cancer. Acid-reflux sufferers that have taken Zantac and other anti-acid medications and subsequently developed cancer should consult a heartburn drug cancer attorney to see if they qualify to file a claim against the drug's manufacturers for negligence and for failing to adequately test the drug before offering it to the public.

According to Breast, "FDA Warns About Probable Carcinogen in Zantac. On Sept. 13, 2019, the U.S. Food and Drug Administration (FDA) warned that some ranitidine medicines, including the medicine commonly known as Zantac, contain very low levels of a compound called N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen based on lab testing." The FDA warns companies that like Sanofi, a division of Novartis, and the maker of Zantac to consider voluntarily recalling drugs that contain high levels of NDMA. "The FDA has advised companies to recall their ranitidine if testing shows levels of NDMA above the acceptable daily intake." Zantac is a ranitidine medication used to treat stomach ulcers, heartburn, and acid reflux. The FDA is not advising patients to stop using acid-reflux medications but is advising people to seek the advice of their doctor to recommend other treatment options such as those sold under the brand names Axid (nizatidine), Pepcid (famotidine), and Tagamet (cimetidine).

Bloomberg has reported that the maker of Zantac has stopped producing the popular anti-acid, fueling speculation that the drug may indeed contain a cancer-causing compound, and has recalled the product overseas. "GlaxoSmithKline Plc, the original branded maker of Zantac, halted global distribution of the popular stomach medicine, adding momentum to actions aimed at stopping access to drugs that are tainted with a potential human carcinogen." Walgreens, Rite-Aid, and CVS have discontinued selling ranitidine medications and have pulled them from shelves nationwide.

In addition to Zantac, other PPIs (protein pump inhibitors) and H2 (histamine2) blockers drugs used to reduce stomach acid and available over the counter may cause cancer as well. Those drugs include Prilosec, Prevacid, and Nexium.

More Recent Heartburn MedicineLawsuit News:

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.